Literature DB >> 32371479

Cytokine Storm Drugs Move from CAR T to COVID-19.

.   

Abstract

Early reports suggest that tocilizumab, an IL6 receptor-blocking antibody used to manage toxicities associated with chimeric antigen receptor T-cell therapy, may help control cytokine storms in people infected with COVID-19. Preliminary data from randomized trials are less clear-cut. ©2020 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32371479     DOI： 10.1158/2159-8290.CD-ND2020-008

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  4 in total

1.  Network pharmacology for the identification of phytochemicals in traditional Chinese medicine for COVID-19 that may regulate interleukin-6.

Authors:  Wen-Hao Niu; Feng Wu; Wen-Yue Cao; Zong-Gui Wu; Yu-Chieh Chao; Chun Liang
Journal:  Biosci Rep       Date:  2021-01-29       Impact factor: 3.840

Review 2.  COVID-19 in cancer patients: risk, clinical features, and management.

Authors:  Cuiwei Liu; Yanxia Zhao; Derick Okwan-Duodu; Reva Basho; Xiaojiang Cui
Journal:  Cancer Biol Med       Date:  2020-08-15       Impact factor: 4.248

3.  Network pharmacology and molecular docking-based investigations of Kochiae Fructus's active phytomolecules, molecular targets, and pathways in treating COVID-19.

Authors:  Shakeel Ahmad Khan; Terence Kin Wah Lee
Journal:  Front Microbiol       Date:  2022-08-05       Impact factor: 6.064

4.  Efficacy and safety of early treatment with sarilumab in hospitalised adults with COVID-19 presenting cytokine release syndrome (SARICOR STUDY): protocol of a phase II, open-label, randomised, multicentre, controlled clinical trial.

Authors:  Rafael León López; Sheila Cárcel Fernández; Laura Limia Pérez; Alberto Romero Palacios; María Concepción Fernández-Roldán; Eduardo Aguilar Alonso; Inés Pérez Camacho; Jesús Rodriguez-Baño; Nicolás Merchante; Julián Olalla; M Ángeles Esteban-Moreno; Marta Santos; Antonio Luque-Pineda; Julian Torre-Cisneros
Journal:  BMJ Open       Date:  2020-11-14       Impact factor: 2.692
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.